Already a subscriber? 
MADCAD.com Free Trial
Sign up for a 3 day free trial to explore the MADCAD.com interface, PLUS access the
2009 International Building Code to see how it all works.
If you like to setup a quick demo, let us know at support@madcad.com
or +1 800.798.9296 and we will be happy to schedule a webinar for you.
Security check
Please login to your personal account to use this feature.
Please login to your authorized staff account to use this feature.
Are you sure you want to empty the cart?
ANSI/AAMI PC76:2021, Active implantable medical devices-Requirements and test protocols for safety of patients with pacemakers and ICDs exposed to magnetic resonance imaging, 2021
- ANSI/AAMI PC76:2021; Active implantable medical devices—Requirements and test protocols for safety of patients with pacemakers and ICDs exposed to
magnetic resonance imaging
- Title page
- AAMI Standard
- Copyright information
- Contents
- Committee representation
- Foreword
- 1 Scope
- 2 Normative references
- 3 Terms and definitions
- 4 Symbols and abbreviated terms
- 5 General requirements for non-implantable parts
- 6 Global malfunction [Go to Page]
- 6.1 Pacing monitoring in radiated environment
- 7 General considerations for application of the tests of this document
- 8 Protection from harm to the patient from lead electrode heating [Go to Page]
- 8.1 General
- 8.2 Hotspot determination
- 8.3 MRI RF lead modelling framework [Go to Page]
- 8.3.1 RF birdcage coils and excitation [Go to Page]
- 8.3.1.1 Coil types
- 8.3.1.2 Coil excitation
- 8.3.1.3 Field rotation
- 8.3.2 Human body library
- 8.3.3 Body position in bore (landmark)
- 8.3.4 Lead pathways [Go to Page]
- 8.3.4.1 Device locations
- 8.3.4.2 Lead tip locations
- 8.3.4.3 Lead pathway definition
- 8.3.5 RF electrical lead model
- 8.4 Model validation [Go to Page]
- 8.4.1 In-vitro lead model validation [Go to Page]
- 8.4.1.1 Phantom selection
- 8.4.1.2 Tissue simulating medium (TSM)
- 8.4.1.3 RF coil and excitation
- 8.4.1.4 Lead paths
- 8.4.1.5 Phantom landmarks
- 8.4.1.6 In-vitro lead model validation data and analysis [Go to Page]
- 8.4.1.6.1 Simulations
- 8.4.1.6.2 Measurements
- 8.4.1.6.3 Data comparison and analysis
- 8.5 Human RF hotspot power prediction [Go to Page]
- 8.5.1 Human body simulations
- 8.5.2 Etan extraction
- 8.5.3 Lead model simulation and pdf
- 8.5.4 Uncertainty analysis
- 8.6 Physiologic response [Go to Page]
- 8.6.1 CEM43 (cumulative equivalent minutes at 43 C)
- 8.6.2 Change in pacing capture threshold (∆PCT) [Go to Page]
- 8.6.2.1 Acute versus chronic insult response
- 8.6.2.2 ∆PCT versus power data set
- 8.6.2.2 Power level determination [Go to Page]
- 8.6.2.2.1 Standard leads
- 8.6.2.2.2 Custom power delivery devices
- 8.6.2.2.3 Power delivery signal loss
- 8.7 Combining simulated power profile with physiologic response [Go to Page]
- 8.7.1 CEM43
- 8.7.2 ∆PCT
- 8.8 Requirement [Go to Page]
- 8.8.1 CEM43
- 8.8.2 ∆PCT [Go to Page]
- 8.8.2.1 Acute insult response requirement while in MRI mode
- 8.8.2.2 Chronic insult response requirement
- 8.9 Cumulative effect
- 9 Protection from harm to the patient from device heating [Go to Page]
- 9.1 Test equipment
- 9.2 Test method [Go to Page]
- 9.2.1 Gradient induced temperature rise due to eddy currents on the device surface (without leads) [Go to Page]
- 9.2.1.1 Tier 1: Temperature measurement in TSM
- 9.2.1.2 Tier 2: Power method
- 9.2.2 RF induced temperature rise from injected RF
- 9.2.3 RF Induced Temperature Rise from local E-field at the CAN
- 9.2.4 Reporting the results from injected and radiated test
- 9.3 Requirement
- 10 Protection from harm to the patient caused by gradient-induced vibration [Go to Page]
- 10.1 Test Method
- 10.2 Magnetic resonance environment [Go to Page]
- 10.2.1 Magnetic field parameters (B0 and dB/dt) [Go to Page]
- 10.2.1.1 CRM devices labeled for a maximum slew rate
- 10.2.1.2 CRM devices labeled for a maximum slew rate of 200 T/m/s per axis
- 10.2.2 Maximum clinical excitation
- 10.2.3 Test duration and temperature
- 10.3 General test procedure [Go to Page]
- 10.3.1 Device setup in an MR scanner
- 10.3.2 Test methods
- 10.3.3 Device monitoring setup
- 10.3.4 Tier 1 Monitoring (if a scanner is used)
- 10.3.5 Method 2 Monitoring (if a shaker table is used)
- 10.4 Assess for device malfunction and damage
- 10.5 Assess for tissue damage
- 11 Protection from harm to the patient caused by B0-induced force [Go to Page]
- 11.1 B0 and B Measurements
- 11.2 B0 and B Measurements [Go to Page]
- 11.2.1 Determining the Z-axis location
- 11.2.2 Determining maximum dB/dz
- 11.3 Lead force measurements [Go to Page]
- 11.3.1 Lead body and distal end force measurements
- 11.3.2 Lead proximal connector force measurement
- 11.4 Device force measurements [Go to Page]
- 11.4.1 Device force measurement system limitations
- 11.5 Force requirements [Go to Page]
- 11.5.1 Tier 1 – Device force limit
- 11.5.2 Tier 2 – Device force limit
- 11.5.3 Lead force limit
- 11.6 Extrapolating the maximum |B| [Go to Page]
- 11.6.1 Extrapolation calculation
- 11.6.2 Labeling requirements
- 12 Protection from harm to the patient caused by B0-induced torque [Go to Page]
- 12.1 ASTM F2213-17
- 12.2 Current induced torque
- 12.3 Lead torque measurements [Go to Page]
- 12.3.1 Lead proximal connector torque measurement
- 12.3.2 Lead body and distal end torque measurements
- 12.4 Device torque measurements
- 12.5 Torque requirements
- 12.6 Device torque limit
- 13 Protection from harm to the patient caused by gradient-induced extrinsic electric potential [Go to Page]
- 13.1 Introduction
- 13.2 General requirements
- 13.3 Annex E, Gradient induced probability of UCS calculation method
- 13.4 PG lead connector, gradient pulse leakage test
- 13.5 PG internal circuit, gradient pulse leakage test [Go to Page]
- 13.5.1 Test equipment
- 13.5.2 Test signal
- 13.5.3 Tier 1- Combined gradient induced charge measurement test procedure
- 13.5.4 Tier 2- Separate transient gradient induced charge and steady state current measurement test procedure [Go to Page]
- 13.5.4.1 Gradient induced charge measurement test procedure
- 13.5.4.2 Gradient induced current measurement test procedure
- 13.6 Gradient rectification test [Go to Page]
- 13.6.1 Test equipment
- 13.6.2 Test signal
- 13.6.3 Gradient induced rectification measurement test procedure
- 13.7 Gradient pulse distortion of PG pace output test [Go to Page]
- 13.7.1 Test equipment
- 13.7.2 Test signal
- 13.7.3 Gradient induced PG output distortion test procedure
- 13.8 PG Test voltages and test case definition [Go to Page]
- 13.8.1 Tier 2 Test voltage definitions and values
- 13.8.2 Tier 3 Test voltage determination [Go to Page]
- 13.8.2.1 Gradient coils and excitation [Go to Page]
- 13.8.2.1.1 Coil types
- 13.8.2.1.2 Gradient coil excitation
- 13.8.2.2 Human body library
- 13.8.2.3 Body position in bore (landmark)
- 13.8.2.4 Lead pathways
- 13.8.3 Pacemaker test cases
- 13.8.4 ICD Test cases
- 13.9 PG Test configurations [Go to Page]
- 13.9.1 Single chamber pacemaker test connections
- 13.9.2 Dual chamber pacemaker test connections
- 13.9.3 Three chamber, bi-ventricular pacemaker
- 13.9.4 Single chamber, single coil ICD
- 13.9.5 Dual chamber, dual coil ICD
- 13.9.6 Three chamber, bi-ventricular, dual coil ICD
- 13.10 Tissue interface network
- 14 Protection from harm to the patient caused by B0-induced malfunction [Go to Page]
- 14.1 General [Go to Page]
- 14.1.1 Scope
- 14.1.2 Testing basis
- 14.2 CIED classes
- 14.3 Static field testing [Go to Page]
- 14.3.1 Scope
- 14.3.2 Compliance criteria
- 14.3.3 B0 field generation
- 14.3.4 Test conditions
- 14.4 Test procedures [Go to Page]
- 14.4.1 Class 0 test [Go to Page]
- 14.4.1.1 Test procedure
- 14.4.2 Class 1 test [Go to Page]
- 14.4.2.1 Test procedure
- 14.4.3 Class 2 test [Go to Page]
- 14.4.3.1 Test procedure
- 14.5 Test equipment [Go to Page]
- 14.5.1 Field generation
- 14.5.2 Phantom and tissue simulating medium
- 14.5.3 CIED monitoring apparatus
- 14.6 Uncertainty assessment
- 15 Protection from harm to the patient caused by RF-induced malfunction and RF rectification [Go to Page]
- 15.1 General
- 15.2 Hazard definition/mechanism
- 15.3 Objective
- 15.4 Assumptions
- 15.5 Test method [Go to Page]
- 15.5.1 Test environment
- 15.5.2 RF Antenna test conditions [Go to Page]
- 15.5.2.1 Modelling method
- 15.5.2.2 Model validation [Go to Page]
- 15.5.2.2.1 15.5.2.2.1 Simulation parameters
- 15.5.2.2.2 Device geometry
- 15.5.2.2.3 Device material properties
- 15.5.2.2.4 Device terminating impedances
- 15.5.3 Injection test setup
- 15.5.4 Determination of test conditions [Go to Page]
- 15.5.4.1 RF-level measurement device
- 15.5.4.2 MRI RF lead modelling framework
- 15.5.4.3 Model validation
- 15.5.4.4 RF level prediction in human
- 15.5.4.5 RF phase conditions
- 15.5.5 Test signal
- 15.5.6 Application of the test signal
- 15.5.7 Rectification and malfunction test procedure [Go to Page]
- 15.5.7.1 Device damage test procedure
- 16 Protection from harm to the patient caused by gradient-induced malfunction [Go to Page]
- 16.1 Introduction
- 16.2 General requirements
- 16.3 Selecting radiated and injected test methods
- 16.4 Radiated immunity test [Go to Page]
- 16.4.1 General
- 16.4.2 Test equipment
- 16.4.3 Radiated test signal
- 16.4.4 Pacemaker test cases
- 16.4.5 ICD test cases
- 16.4.6 Test procedure
- 16.5 Injected immunity test [Go to Page]
- 16.5.1 General
- 16.5.2 Test equipment
- 16.5.3 Injected test signal
- 16.5.4 Pacemaker test cases
- 16.5.5 ICD test cases
- 16.5.6 Test procedure
- 16.5.7 Test configurations
- 17 Combined fields test [Go to Page]
- 17.1 Test equipment
- 17.2 Test setup
- 17.3 System fixation
- 17.4 Test procedure [Go to Page]
- 17.4.1 Before MR exposure
- 17.4.2 During MR exposure
- 17.4.3 After MR exposure
- 17.5 Compliance criteria
- Annex A (informative) RF injection method utilizing standard leads [Go to Page]
- A.1 General
- A.2 Measurement to address the concern of common mode at 500 kHz
- Annex B (informative) Use of standard production leads to deliver a target RF power at 64 MHz to the myocardium in an animal test [Go to Page]
- B.1 General
- B.2 Procedure
- Annex C (informative) CEM43 C (cumulative equivalent minutes at 43 C) [Go to Page]
- C.1 General
- C.2 CEM43 for heart and skeletal muscle
- C.3 CEM43 for the pocket tissue [Go to Page]
- C.3.1 Skin [Go to Page]
- C.3.1.1 Starting temperature
- C.3.1.2 Acceptance criteria free from chronic damage
- C.3.1.3 Acceptance criteria free from pain
- C.3.2 Muscle [Go to Page]
- C.3.2.1 Starting temperature
- C.3.2.2 Acceptance criteria free from chronic damage
- C.3.3 Scar material
- C.4 CEM43 C for the tissue in contact with the lead body
- C.5 Scan duration
- Annex D (informative) In vivo temperature rise in response to applied heat flux [Go to Page]
- D.1 Background
- D.2 Applicable data
- D.3 Analysis
- D.4 Result
- Annex E (normative) Gradient P(UCS) calculation method [Go to Page]
- E.1 General
- E.2 PDF of Capture Thresholds (Qmin, Rheobase)
- E.3 Probability analysis
- E.4 Gradient induced charge and current limits (QGRAD_MAX, IGRAD_MAX)
- Annex F (normative) RF UCS Compliance criteria [Go to Page]
- F.1 General
- F.2 Stress determination [Go to Page]
- F.2.1 Tier 1 [Go to Page]
- F.2.1.1 See 15.5.4 for information on the determination of test conditions and device malfunction. Leverage the RF modelling framework to generate a set of in-human use conditions that define the peak (30 µT) RF levels at the lead electrode RF entry p...
- F.2.1.2 Determine the 99th percentile RF level at each RF entry points into a device and identify the maximum of the 99th percentile RF levels. Use this maximum 99th percentile RF level as the test level for all lead electrode RF entry points into a d...
- F.2.1.3 Include phase variation in the testing by applying 0 , 90 , 180 , and 270 phase shift to each RF entry point, one at a time, while injecting RF energy into other RF entry points at 0 .
- F.2.1.4 See 15.5.2 for information on the RF antenna test to determine the telemetry antenna injection level. Test the lead electrode test level identified in step 2 with the simultaneous antenna injection level determined in step 7 of 15.5.2.1 cycled...
- F.2.1.5 Perform direct RF-injection test at magnitude and phase condition of each RF entry point. Record the magnitude of rectification pulse for each electrode with respect to case.
- F.2.1.6 For each electrode, fit the rectification voltage (or current) to an appropriate distribution. Determine the 99th upper tolerance limit with a confidence/reliability of 95/99.
- F.2.2 Tiers 2 or 3 – Vector generation [Go to Page]
- F.2.2.1 In the case of RF rectification, PDF of stress is essentially the PDF of rectified voltage which can be determined by the steps in F.2.2.2 through F.2.2.7.
- F.2.2.2 See 15.5.4 for addition information. Leverage the RF modelling framework to generate a set of in-human use conditions that define the peak (30 µT) RF levels at the RF entry points into a device, with RF phase conditions of 15.5.4.5.
- F.2.2.3 Sort the use conditions from max to min by total power across all RF entry points to generate the PDF of total power.
- F.2.2.4 Span the test vectors from the region of the PDF of total power between the upper bound of the worst-case power and the lower bound resulting in safe levels of rectification as defined by voltage, current or charge. Unique test cases are deter...
- F.2.2.5 If phase cycling is used, for each test vector, include that phase variation by applying 0 , 90 , 180 , and 270 phase shift to each RF entry point, one at a time, while injecting RF energy into other RF entry points at 0 . Note that the ...
- F.2.2.6 See 15.5.2 to determine the telemetry antenna injection levels. Test each test vector identified in previous steps with the antenna injection level determined in step 7 of 15.5.2.1 cycled in phase increments and conditions as specified in 15.5...
- F.2.2.7 Perform direct RF-injection test at corresponding magnitude and phase condition of each RF entry point. Record the magnitude of rectification pulse for each electrode with respect to case. Typically, the AV and VV delays in MRI mode remove the...
- F.2.3 Tier 2 - Injection and analysis [Go to Page]
- F.2.3.1 For each test vector, take the maximum rectification differential across any pair of electrodes and plot total power vs. rectified voltage (or current) for all vectors tested (Figure F.3). Fit the maximum rectified voltage (or current) at diff...
- F.2.3.2 For all power levels less than the minimum tested injection level, assume the rectification is equal to the measured rectification at the minimum injection level.
- F.2.3.3 Convert the PDF of total power to the PDF of rectified voltage using the relationship defined in F.2.3.1 and F.2.3.2.
- F.2.4 Tier 3 - Injection and analysis [Go to Page]
- F.2.4.1 For each electrode, plot rectification voltage (or current) vs injected voltage across all vectors tested. Fit the maximum rectified voltage (or current) vs injected voltage to approximate rectified voltage (or current) over entire RF-injectio...
- F.2.4.2 For all levels less than the minimum tested injection level, assume the rectification is equal to the measured rectification at the minimum injection level.
- F.2.4.3 Convert the PDF of each electrode to the PDF of rectified voltage using the relationship defined in F.2.4.1 and F.2.4.2.
- F.3 Strength determination [Go to Page]
- F.3.1 PDF of strength is essentially the PDF of stimulation voltage required to obtain sustained capture.
- F.3.2 Determine the PDF of stimulation voltage required to obtain sustained capture for electrode(s) evaluated. This information is typically available through clinical data.
- F.3.3 Calculate the capture stimulation threshold at the measured rectified PW using the strength-duration relationship. If a large transient occurs, the pulse width of the transient shall also be assessed. Specifically, rheobase and chronaxie can be ...
- F.3.4 Generate the PDF of stimulation voltage using all data points from F.3.2 and F.3.3. As specified in Reilly [49], cardiac stimulation typically follows a lognormal distribution.
- F.4 Acceptance criteria
- Annex G (informative) Example of implementation of MR scan protocols for combined fields [Go to Page]
- G.1 General
- G.2 Neurological examinations examples
- G.3 Thoracic examinations examples
- G.4 Upper limbs examinations examples
- G.5 Pelvic examinations examples
- Bibliography [Go to Page]
